biOasis commences research agreement with NRC

biOasis Technologies Inc. (TSX-V:BTI) announced today that it has commenced a sponsored research agreement with the National Research Council ("NRC") of Canada.  Under the terms of the agreement, the NRC will evaluate the ability of biOasis' compounds to cross the blood-brain barrier using time-domain in vivo optical imaging.

 "This is an important step in the development of Transcend™," says CEO Rob Hutchison. "The agreement with the NRC will provide the company with demonstration of the ability of Transcend^TM to carry a fluorescent dye that is normally excluded from the brain, across the blood-brain barrier.  This will enable its visualization and localization in brain tissue and further add to our understanding of the potential for Transcend^TM to deliver therapeutic agents into the brain.  We anticipate that this information will be of great interest to prospective partners and licensees of biOasis' technologies."